- Elan and Biogen Idec shares plunged after suspending sales of Tysabri.
- Sales were suspended after a patient's death in the US.
- Phytopharm shares also closed down after a partner pulled out of a deal.
- Tysabri was approved for use in the US last November.
- It was widely tipped to become the world's leading multiple sclerosis treatment.
- The cases cited involved the use of both Tysabri and Avonex.
- Most of Elan's value was in Tysabri.
